ReviewUrologie (Heidelberg, Germany)2025
[Personalized systemic therapy of penile cancer: molecular targets and new therapeutic horizons].
Review in Urologie (Heidelberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPenile cancer is a rare urological malignancy with approximately 36,000 new cases worldwide each year. In the first-line setting of locally advanced or metastatic disease, platinum-based chemotherapy is recommended, but it yields only moderate response rates, short remission durations, and considerable toxicity. Effective second-line treatment options are largely lacking, underscoring the urgent need for innovative therapeutic approaches.
objectiveThis article aims to summarize current evidence on immunotherapeutic and targeted treatment strategies in advanced penile cancer. MATERIAL AND
methodsA systematic literature search was conducted in PubMed, complemented by recent abstracts and presentations from major congresses (American Society of Clinical Oncology, ASCO; ASCO Genitourinary, ASCO GU; European Society for Medical Oncology, ESMO) and clinical trial registries (clinicaltrials.gov).
resultsImmune checkpoint inhibitor monotherapy demonstrates response rates of 13-17% in unselected cohorts, with improved outcomes in patients with high tumor mutational burden or exclusively nodal metastases. In combination with chemotherapy, response rates increased to around 40%. Epidermal growth factor receptor (EGFR)-targeted antibodies achieved remissions in approximately one third of patients, albeit generally of short duration. Based on expression patterns of various surface proteins (EGFR, HER2, Nectin‑4, Trop-2), several antibody-drug conjugates are currently being evaluated in phase II trials. Moreover, poly ADP ribose polymerase (PARP) inhibition may represent a rational option in tumors harboring alterations in homologous recombination repair genes.
conclusionImmuno- and targeted therapies open new perspectives for the management of advanced penile cancer. Because of the rarity of this malignancy, international collaborations are crucial to ensure adequate trial recruitment. Such efforts are essential to render innovative approaches accessible to a broader patient population and to strengthen the evidence base for future treatment strategies.
Indexed as
Identifiers
41222675What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.